Serum level of fibroblast growth factor 23 in maintenance renal transplant patients

Nephrology Dialysis Transplantation

Volumn 27, Issue 11, 2012, Pages 4227-4235

  Sánchez Fructuoso, Ana I ^a   Maestro, Maria L ^a   Pérez Flores, Isabel ^a   Valero, Rosalía ^a   Rafael, Sara ^a   Veganzones, Silvia ^a   Calvo, Natividad ^a   De La Orden, Virginia ^a   De La Flor, Jose C ^a   Valga, Francisco ^a   Vidaurreta, Marta ^a   Fernández Pérez, Cristina ^a   Barrientos, Alberto ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

fibroblast growth factor 23; hyperparathyroidism; hypophosphataemia; kidney transplantation; post transplant bone disease

Indexed keywords

ANTIMETABOLITE; BICARBONATE; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCITRIOL; CINACALCET; COLECALCIFEROL; CORTICOSTEROID; FIBROBLAST GROWTH FACTOR 23; MAGNESIUM; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; BONE DISEASE; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; DIET SUPPLEMENTATION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ABSORPTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; BONE DENSITY; CALCITRIOL; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84869462410     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs409     Document Type: Article

References (43)

1. Ghanekar H, Welch B, Moe O et al. Post-renal transplantation hypo-phosphatemia: a review and novel insights. Curr Opin Nephrol Hy-pertens 2006; 15:97-104.
2. David DS, Sakal S, Brennan L et al. Hypercalcemia after renal transplantation: Long-term follow-up data. N Engl J Med 1973; 289:398-401.
3. Ozdemir FN, Afsar B, Akgul A et al. Persistent hypercalcemia is a significant risk factor for graft dysfunction in renal transplantation recipients. Transplant Proc 2006; 38:480-482.
4. Gwinner W, Suppa S, Mengel M et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005; 5:1934-1941. (Pubitemid 41039868)
5. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15:2857-2867. (Pubitemid 41103395)
6. Levi M. Post-transplant hypophosphatemia. Kidney Int 2001; 59:2377-2387. (Pubitemid 32467638)
7. Evenepoel P, Meijers B, de Jonge H et al. Recovery of hyperphospha-toninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008; 3:1829-1836.
8. Green J, Debby H, Lederer Eet al. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phos-phaturia. Kidney Int 2001; 60:1182-1196. (Pubitemid 34205819)
9. Kawarazaki H, Shibagaki Y, Shimizu H et al. Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypo-phosphatemia. Clin Exp Nephrol 2007; 11:255-257. (Pubitemid 47476798)
10. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18:1637-1647. (Pubitemid 46870300)
11. Yamazaki Y, Tamada T, Kasai N et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 2008; 23:1509-1518.
12. Yoshiko Y, Wang H, Minamizaki Tet al. Mineralized tissue cells are a principal source of FGF23. Bone 2007; 40:1565-1573. (Pubitemid 46756409)
13. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff Vet al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117:4003-4008. (Pubitemid 350224109)
14. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281:6120-6123. (Pubitemid 43847540)
15. Nakatani T, Ohnishi M, Razzaque MS. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEBJ2009; 23:3702-3711.
16. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584-592.
17. Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005; 67:1120-1125. (Pubitemid 41623338)
18. Nakanishi S, Kazama JJ, Nii-Kono T et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67:1171-1178. (Pubitemid 41623344)
19. Isakova T, Xie H, Yang W et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305:2432-2439.
20. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79:1370-1378.
21. Evenepoel P, Meijers B, Viaene L et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5:1268-1276.
22. Pereira RC, Juppner H, Azucena-Serrano CE et al. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009; 45:1161-1168.
23. Filler G, Liu D, Huang SH et al. Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease. Clin Biochem 2011; 44:435-437.
24. Danziger J. The bone-renal axis in early chronic kidney disease: an emerging paradigm. Nephrol Dial Transplant 2008; 23:2733-2737.
25. Bhan I, Shah A, Holmes J et al. Post-transplant hypophosphatemia: tertiary 'Hyper-Phosphatoninism'? Kidney Int 2006:70:1486-1494. (Pubitemid 44527320)
26. Evenepoel P, Naesens M, Claes K et al. Tertiary 'hyperphosphatonin-ism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007; 7:1193-1200. (Pubitemid 46643105)
27. Economidou D, Dovas S, Papagianni A et al. FGF-23 levels before and after renal transplantation. J Transplant 2009; 2009:379-382.
28. Sato T, Fukagawa M, Uchida K et al. 1, 25-dihydroxyvitamin D synthesis after renal transplantation: the role of fibroblast growth factor 23 and cyclosporine. Clin Transplant 2009; 23:368-374.
29. Trombetti A, Richert L, Hadaya K et al. Early post-transplantation hypophosphatemia is associated with elevated FGF-23 levels. Eur J Endocrinol 2011; 164:839-847.
30. Kanaan N, Claes K, Devogelaer JP et al. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. Clin J Am Soc Nephrol 2010; 5:1887-1892.
31. Pande S, Ritter CS, Rothstein M et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006; 104:23-32.
32. Kawarazaki H, Shibagaki Y, Fukumoto S et al. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. Nephrol Dial Transplant 2011; 26:2691-2695.
33. Seeherunvong W, Wolf M. Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation. Pediatr Transplant 2011; 15:37-46.
34. Wesseling-Perry K, Tsai EW, Ettenger RB et al. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant 2011; 26:3779-3784.
35. Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol. 2011; 22:956-966.
36. Manjunath G, Sarnak MJ, Levey AS. Estimating the glomerular filtration rate. Dos and don'ts for assessing kidney function. Postgrad Med 2001; 110:55-62. (Pubitemid 33140598)
37. Bijvoet OL. Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin Sci 1969; 37:23-36.
38. Human intact FGF-23 ELISA Kit Enzyme-linked ImmunoSorbent Assay (ELISA) for the Determination of Human Fibroblast Growth Factor 23 Levels in Plasma or Cell Culture Media. http://www. immutopics.com/pdf/directional-inserts/60-6500. pdf
39. Kleimbaum DG, Kupper LL, Muller KE. Applied Regression Analysis and Other Multivariable Methods. Boston: PWS-KENT, 1988, pp. 324-325
40. Weisinger JR, Carlini RG, Rojas E et al. Bone disease after renal transplantation. Clin J Am Soc Nephrol 2006; 1:1300-1313.
41. Samadfam R, Richard C, Nguyen-Yamamoto L et al. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009; 150:4835-4845.
42. Bacchetta J, Dubourg L, Harambat J et al. The influence of glomer-ular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 2010; 95:1741-1748.
43. Pöge U, Gerhardt T, Palmedo H et al. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005; 5:1306-1311. (Pubitemid 40839418)